应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02509 荃信生物-B
已收盘 07-03 16:08:13
19.240
+1.360
+7.61%
最高
19.660
最低
18.020
成交量
2.24万
今开
19.660
昨收
17.880
日振幅
9.17%
总市值
42.73亿
流通市值
39.39亿
总股本
2.22亿
成交额
42.77万
换手率
0.01%
流通股本
2.05亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
荃信生物(02509.HK)共斥2.6亿人币认购理财产品
阿斯达克财经 · 09:20
荃信生物(02509.HK)共斥2.6亿人币认购理财产品
荃信生物-B(02509):认购理财产品
智通财经网 · 07-02 19:32
荃信生物-B(02509):认购理财产品
荃信生物-B(02509)股价上升8.415%,现价港币$19.84
阿斯达克财经 · 07-02 14:10
荃信生物-B(02509)股价上升8.415%,现价港币$19.84
荃信生物-B(02509)股价下跌8.073%,现价港币$25.05
阿斯达克财经 · 06-27
荃信生物-B(02509)股价下跌8.073%,现价港币$25.05
荃信生物-B(02509)股价显著上升12.527%,现价港币$26.5
阿斯达克财经 · 06-18
荃信生物-B(02509)股价显著上升12.527%,现价港币$26.5
荃信生物直线拉升涨超11% 股价收复近半个月失地
金融界 · 06-18
荃信生物直线拉升涨超11% 股价收复近半个月失地
港股异动 | 荃信生物-B(02509)午后涨超10% 治疗PN注射液研究结果显示主要终点达标
智通财经 · 06-18
港股异动 | 荃信生物-B(02509)午后涨超10% 治疗PN注射液研究结果显示主要终点达标
荃信生物(02509.HK)治疗PN注射液研究结果显示主要终点达标
阿斯达克财经 · 06-16
荃信生物(02509.HK)治疗PN注射液研究结果显示主要终点达标
荃信生物-B:QX005N注射液治疗PN II期临床显著疗效,76.7%患者瘙痒改善
和讯网 · 06-14
荃信生物-B:QX005N注射液治疗PN II期临床显著疗效,76.7%患者瘙痒改善
荃信生物-B(02509.HK):QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据于中华
智通财经 · 06-14
荃信生物-B(02509.HK):QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据于中华
荃信生物-B(02509):QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据于中华医学会第二十九次皮肤性病学术年会发布
智通财经 · 06-14
荃信生物-B(02509):QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据于中华医学会第二十九次皮肤性病学术年会发布
荃信生物-B(02509)股价下跌5.063%,现价港币$22.5
阿斯达克财经 · 06-12
荃信生物-B(02509)股价下跌5.063%,现价港币$22.5
港股异动 | 荃信生物-B(02509)涨超7% QX005N结节性痒疹Ⅲ期临床试验顺利达成首例受试者入组
智通财经 · 05-30
港股异动 | 荃信生物-B(02509)涨超7% QX005N结节性痒疹Ⅲ期临床试验顺利达成首例受试者入组
荃信生物(02509.HK)QX005N注射液III期临床试验达成首例受试者入组
阿斯达克财经 · 05-29
荃信生物(02509.HK)QX005N注射液III期临床试验达成首例受试者入组
荃信生物-B(02509):QX005N结节性痒疹III期临床试验顺利达成首例受试者入组
智通财经 · 05-29
荃信生物-B(02509):QX005N结节性痒疹III期临床试验顺利达成首例受试者入组
荃信生物:华东医药“输血”下自免赛道的探索者
观察者网 · 05-24
荃信生物:华东医药“输血”下自免赛道的探索者
荃信生物-B(02509)股价下跌5.479%,现价港币$27.6
阿斯达克财经 · 05-16
荃信生物-B(02509)股价下跌5.479%,现价港币$27.6
港股异动 | 荃信生物-B(02509)涨超6%创上市新高 QX013N慢性自发性荨麻疹适应症获批临床
智通财经 · 05-13
港股异动 | 荃信生物-B(02509)涨超6%创上市新高 QX013N慢性自发性荨麻疹适应症获批临床
荃信生物(02509.HK)单克隆抗体获新药临床试验许可
阿斯达克财经 · 05-10
荃信生物(02509.HK)单克隆抗体获新药临床试验许可
加载更多
公司概况
公司名称:
荃信生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事自身免疫及过敏性疾病生物疗法的生物科技研发。该公司业务主要涵盖四大疾病领域,包括皮肤、风湿、呼吸道及消化道疾病。该公司正在研发的项目有8个,目标适应症包括银屑病、特应性皮炎、类风湿性关节炎、炎症性肠病、哮喘等。该公司核心产品有QX002N和QX005N。
发行价格:
--
{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"荃信生物-B","latestPrice":19.24,"timestamp":1719994093015,"preClose":17.88,"halted":0,"volume":22400,"delay":0,"floatShares":204749200,"shares":222071600,"eps":-2.6389432,"marketStatus":"已收盘","marketStatusCode":5,"change":1.36,"latestTime":"07-03 16:08:13","open":19.66,"high":19.66,"low":18.02,"amount":427712,"amplitude":0.091723,"askPrice":19.26,"askSize":1400,"bidPrice":18.42,"bidSize":400,"shortable":0,"etf":0,"ttmEps":-2.6389431614349776,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1720056600000},"adr":0,"listingDate":1710864000000,"adjPreClose":17.88,"openAndCloseTimeList":[[1719970200000,1719979200000],[1719982800000,1719993600000]],"volumeRatio":0.187041,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509","defaultTab":"news","newsList":[{"id":"2448602117","title":"荃信生物(02509.HK)共斥2.6亿人币认购理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2448602117","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448602117?lang=zh_cn&edition=full","pubTime":"2024-07-03 09:20","pubTimestamp":1719969600,"startTime":"0","endTime":"0","summary":"荃信生物(02509.HK) 公布,于今年4月至6月,分别与浦发银行(600000.SH) 、江苏银行(600919.SH) 及工商银行(01398.HK) 签订认购协议,认购本金额合共为2.6亿元人民币的理财产品。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-02 16:25。) (A股报价延迟最少十五分钟。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1360972/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2448898130","title":"荃信生物-B(02509):认购理财产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2448898130","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448898130?lang=zh_cn&edition=full","pubTime":"2024-07-02 19:32","pubTimestamp":1719919927,"startTime":"0","endTime":"0","summary":"荃信生物-B(02509)发布公告,公司已分别与浦发银行、江苏银行及工商银行签订认...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_2.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_2.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2448900653","title":"荃信生物-B(02509)股价上升8.415%,现价港币$19.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2448900653","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448900653?lang=zh_cn&edition=full","pubTime":"2024-07-02 14:10","pubTimestamp":1719900600,"startTime":"0","endTime":"0","summary":"[上升股]荃信生物-B(02509) 股价在下午02:10比前收市价上升8.415%,现股价为港币$19.84。至目前为止,今日最高价为$19.84,而最低价为$16.8。总成交量为7.8万股,总成交金额为港币$137.757万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407022699/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2446320344","title":"荃信生物-B(02509)股价下跌8.073%,现价港币$25.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2446320344","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446320344?lang=zh_cn&edition=full","pubTime":"2024-06-27 10:00","pubTimestamp":1719453600,"startTime":"0","endTime":"0","summary":"[下跌股]荃信生物-B(02509) 股价在上午10:00比前收市价下跌8.073%,现股价为港币$25.05。至目前为止,今日最高价为$27.2,而最低价为$25.05。总成交量为1.18万股,总成交金额为港币$30.926万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2406271435/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2444170526","title":"荃信生物-B(02509)股价显著上升12.527%,现价港币$26.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2444170526","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444170526?lang=zh_cn&edition=full","pubTime":"2024-06-18 15:32","pubTimestamp":1718695920,"startTime":"0","endTime":"0","summary":"[上升股]荃信生物-B(02509) 股价在下午03:32比前收市价显著上升12.527%,现股价为港币$26.5。至目前为止,今日最高价为$26.5,而最低价为$23.0。总成交量为11.22万股,总成交金额为港币$278.589万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2406181017/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2444780172","title":"荃信生物直线拉升涨超11% 股价收复近半个月失地","url":"https://stock-news.laohu8.com/highlight/detail?id=2444780172","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444780172?lang=zh_cn&edition=full","pubTime":"2024-06-18 15:13","pubTimestamp":1718694833,"startTime":"0","endTime":"0","summary":"港股自身免疫第一股荃信生物-B午后直线拉升,一度大涨11.46%至26.25港元,股价收复近半个月失地,市值重回58亿港元上方。该试验为国内首个由中国企业开展的针对PN适应症的生物药临床试验,基于该项试验数据,QX005N于今年1月31日被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。该行认为特应性皮炎生物制剂与银屑病药物需求增长将较快。","market":"hk","thumbnail":"http://imgcloud.jrjimg.cn/2024/06/cms_20240618151353696.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2024/06/cms_20240618151353696.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/18151341070323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2444387176","title":"港股异动 | 荃信生物-B(02509)午后涨超10% 治疗PN注射液研究结果显示主要终点达标","url":"https://stock-news.laohu8.com/highlight/detail?id=2444387176","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444387176?lang=zh_cn&edition=full","pubTime":"2024-06-18 14:04","pubTimestamp":1718690640,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,荃信生物-B(02509)午后放量拉升逾10%,截至发稿,涨4.25%,报24.55港元,成交额213.89万港元。消息面上,荃信生物公布,QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据在中华医学会第二十九次皮肤性病学术年会上以口头报告形式发布。基于试验数据,QX005N于今年1月31日被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。据悉,该试验为国内首个由内地企业开展针对PN适应症的生物药临床试验,研究结果显示,本次临床试验各剂量组的主要终点完全达标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07226","02509","BK1161","HSCEI","YANG","HSTECH"],"gpt_icon":0},{"id":"2443792482","title":"荃信生物(02509.HK)治疗PN注射液研究结果显示主要终点达标","url":"https://stock-news.laohu8.com/highlight/detail?id=2443792482","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443792482?lang=zh_cn&edition=full","pubTime":"2024-06-16 18:33","pubTimestamp":1718533980,"startTime":"0","endTime":"0","summary":"荃信生物-B(02509.HK) 公布,QX005N注射液治疗结节性痒疹“PN”II期临床试验数据在中华医学会第二十九次皮肤性病学术年会上以口头报告形式发布。基于试验数据,QX005N于今年1月31日被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。该试验为国内首个由内地企业开展针对PN适应症的生物药临床试验,研究结果显示,本次临床试验各剂量组的主要终点完全达标。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1356712/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2443622786","title":"荃信生物-B:QX005N注射液治疗PN II期临床显著疗效,76.7%患者瘙痒改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2443622786","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443622786?lang=zh_cn&edition=full","pubTime":"2024-06-14 20:38","pubTimestamp":1718368711,"startTime":"0","endTime":"0","summary":"快讯正文荃信生物-B近日宣布,其QX005N注射液在治疗结节性痒疹的II期临床试验中取得积极成果。研究结果表明,QX005N注射液在各剂量组中均显示出显著的疗效。在第16周,300mg、450mg及600mg组的WI-NRS评分改善率分别为76.7%、83.3%及76.7%,远高于安慰剂组的30.0%。在改善皮损方面,各剂量组的表现也优于安慰剂组,显示出QX005N在治疗PN方面的潜力。安全性评估显示,QX005N注射液的耐受性良好,未观察到严重的药物相关不良事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406142040429f3d1643&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406142040429f3d1643&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2443625430","title":"荃信生物-B(02509.HK):QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据于中华","url":"https://stock-news.laohu8.com/highlight/detail?id=2443625430","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443625430?lang=zh_cn&edition=full","pubTime":"2024-06-14 19:21","pubTimestamp":1718364115,"startTime":"0","endTime":"0","summary":"智通财经APP讯, 荃信生物-B (02509.HK)公布,QX005N注射液治疗结节性痒疹(PN)的II期临床试验(CTR20223174)数据在中华医学会第二十九次皮肤性病学术年会上以口头报告形式发布。该试验为国内首个由中国企业开展的针对PN适应症的生物药临床试验,基于该项试验数据,QX005N于今年1月31日被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406141930499f3ce749&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406141930499f3ce749&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","03347","BK1583","02509","BK1576","BK1141"],"gpt_icon":0},{"id":"2443611640","title":"荃信生物-B(02509):QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据于中华医学会第二十九次皮肤性病学术年会发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2443611640","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443611640?lang=zh_cn&edition=full","pubTime":"2024-06-14 18:33","pubTimestamp":1718361184,"startTime":"0","endTime":"0","summary":"智通财经APP讯,荃信生物-B 公布,QX005N注射液治疗结节性痒疹的II期临床试验数据在中华医学会第二十九次皮肤性病学术年会上以口头报告形式发布。该试验为国内首个由中国企业开展的针对PN适应症的生物药临床试验,基于该项试验数据,QX005N于今年1月31日被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。此外,QX005N于给药首周即快速起效,并在第16周给药结束后,瘙痒改善疗效维持至第24周随访结束。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1135566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","03347","BK1583","02509","BK1576","BK1141"],"gpt_icon":0},{"id":"2442743243","title":"荃信生物-B(02509)股价下跌5.063%,现价港币$22.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2442743243","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442743243?lang=zh_cn&edition=full","pubTime":"2024-06-12 10:25","pubTimestamp":1718159100,"startTime":"0","endTime":"0","summary":"[下跌股]荃信生物-B(02509) 股价在上午10:25比前收市价下跌5.063%,现股价为港币$22.5。至目前为止,今日最高价为$23.9,而最低价为$22.5。总成交量为2.5万股,总成交金额为港币$57.755万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2406121840/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2439662486","title":"港股异动 | 荃信生物-B(02509)涨超7% QX005N结节性痒疹Ⅲ期临床试验顺利达成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2439662486","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439662486?lang=zh_cn&edition=full","pubTime":"2024-05-30 14:21","pubTimestamp":1717050065,"startTime":"0","endTime":"0","summary":"消息面上,荃信生物宣布,公司自主研发的QX005N注射液达成结节性痒疹Ⅲ期临床试验首例受试者入组,这是国内首个由中国企业开展的针对PN适应症的III期临床试验。据悉,该试验是一项评价QX005N在治疗结节性痒疹成人受试者中的有效性和安全性的多中心、随机、双盲、安慰剂对照的III期临床研究,其主要研究目的是评估QX005N在PN受试者中对瘙痒缓解的有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1128225.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","02509","HSCEI","07226","BK1583","BK1161","HSTECH","BK1576","YANG","03347"],"gpt_icon":0},{"id":"2439276576","title":"荃信生物(02509.HK)QX005N注射液III期临床试验达成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2439276576","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439276576?lang=zh_cn&edition=full","pubTime":"2024-05-29 22:56","pubTimestamp":1716994560,"startTime":"0","endTime":"0","summary":"荃信生物-B(02509.HK) 公布,公司自主研发的QX005N注射液结节性痒疹“PN”III期临床试验达成首例受试者入组,是首个由内地企业开展的针对PN适应症的III期临床试验。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1352967/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02509","BK1161","BK1583","BK4134","III","BK1576","03347","BK1141"],"gpt_icon":0},{"id":"2439544438","title":"荃信生物-B(02509):QX005N结节性痒疹III期临床试验顺利达成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2439544438","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439544438?lang=zh_cn&edition=full","pubTime":"2024-05-29 18:54","pubTimestamp":1716980088,"startTime":"0","endTime":"0","summary":"智通财经APP讯,荃信生物-B 发布公告,于2024年5月29日,公司自主研发的QX005N注射液结节性痒疹III期临床试验达成首例受试者入组,这是国内首个由中国企业开展的针对PN适应症的III期临床试验。本试验是一项评价QX005N在治疗PN成人受试者中的有效性和安全性的多中心、随机、双盲、安慰剂对照的III期临床研究,其主要研究目的是评估QX005N在PN受试者中对瘙痒缓解的有效性。2024年5月10日,QX005N针对成人中重度特应性皮炎的III期临床试验达成首例受试者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1127838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509","BK1141","03347","III","BK1576","BK4134","BK1583"],"gpt_icon":0},{"id":"2437035880","title":"荃信生物:华东医药“输血”下自免赛道的探索者","url":"https://stock-news.laohu8.com/highlight/detail?id=2437035880","media":"观察者网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437035880?lang=zh_cn&edition=full","pubTime":"2024-05-24 19:21","pubTimestamp":1716549685,"startTime":"0","endTime":"0","summary":"作为港交所2024年首个“18A”公司,荃信生物在免疫赛道上的前景似乎并不乐观。作为荃信生物的重要股东,华东医药此次投资无疑承载着巨大的期待。荃信生物股价的破发,或许只是免疫赛道竞争激烈的冰山一角。根据协议,荃信生物将授予中美华东在中国的联合临床开发、生产及独家商业化QX001S的权利,并保留该药物在中国境外的全部开发及商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524192252aef18f7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240524192252aef18f7f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2435564472","title":"荃信生物-B(02509)股价下跌5.479%,现价港币$27.6","url":"https://stock-news.laohu8.com/highlight/detail?id=2435564472","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435564472?lang=zh_cn&edition=full","pubTime":"2024-05-16 14:30","pubTimestamp":1715841000,"startTime":"0","endTime":"0","summary":"[下跌股]荃信生物-B(02509) 股价在下午02:30比前收市价下跌5.479%,现股价为港币$27.6。至目前为止,今日最高价为$30.55,而最低价为$27.6。总成交量为8.74万股,总成交金额为港币$254.243万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2405162415/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2435312837","title":"港股异动 | 荃信生物-B(02509)涨超6%创上市新高 QX013N慢性自发性荨麻疹适应症获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2435312837","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435312837?lang=zh_cn&edition=full","pubTime":"2024-05-13 14:44","pubTimestamp":1715582674,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,荃信生物-B涨超6%,高见28.85港元创上市新高。截至发稿,涨5.9%,报28.7港元,成交额347.35万港元。消息面上,荃信生物近日公布,公司自主研发的人源化IgG1单克隆抗体QX013N获得国家药监局药品审评中心的新药临床试验许可,用于治疗慢性自发性荨麻疹。QX013N是中国首款针对c-kit靶点的候选生物药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSTECH","07226","02509","HSCEI","YANG","BK1161"],"gpt_icon":0},{"id":"2434045892","title":"荃信生物(02509.HK)单克隆抗体获新药临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2434045892","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434045892?lang=zh_cn&edition=full","pubTime":"2024-05-10 01:40","pubTimestamp":1715276400,"startTime":"0","endTime":"0","summary":"荃信生物-B(02509.HK) 公布,公司自主研发的人源化IgG1单克隆抗体QX013N获中国国家药品监督管理局药品审评中心的新药临床试验许可,用于治疗慢性自发性荨麻疹“CSU”。是内地首款针对c-kit靶点的候选生物药物。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1348583/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","02509","BK1161","BK1141","BK1576","03347"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":-0.3533},{"period":"1month","weight":-0.339},{"period":"3month","weight":-0.2053},{"period":"6month","weight":-0.097},{"period":"ytd","weight":-0.097}],"compareEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":-0.0172},{"period":"3month","weight":0.0624},{"period":"6month","weight":0.0675},{"period":"1year","weight":-0.0796},{"period":"ytd","weight":0.0423}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事自身免疫及过敏性疾病生物疗法的生物科技研发。该公司业务主要涵盖四大疾病领域,包括皮肤、风湿、呼吸道及消化道疾病。该公司正在研发的项目有8个,目标适应症包括银屑病、特应性皮炎、类风湿性关节炎、炎症性肠病、哮喘等。该公司核心产品有QX002N和QX005N。","exchange":"SEHK","name":"荃信生物-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荃信生物-B,02509,荃信生物-B股票,荃信生物-B股票老虎,荃信生物-B股票老虎国际,荃信生物-B行情,荃信生物-B股票行情,荃信生物-B股价,荃信生物-B股市,荃信生物-B股票价格,荃信生物-B股票交易,荃信生物-B股票购买,荃信生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}